GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (NAS:ONC) » Definitions » Gross Profit

ONC (BeOne Medicines) Gross Profit : $3,216 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BeOne Medicines Gross Profit?

BeOne Medicines's gross profit for the three months ended in Dec. 2024 was $967 Mil. BeOne Medicines's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $3,216 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BeOne Medicines's gross profit for the three months ended in Dec. 2024 was $967 Mil. BeOne Medicines's Revenue for the three months ended in Dec. 2024 was $1,128 Mil. Therefore, BeOne Medicines's Gross Margin % for the quarter that ended in Dec. 2024 was 85.76%.

BeOne Medicines had a gross margin of 85.76% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of BeOne Medicines was 97.91%. The lowest was 77.12%. And the median was 84.48%.


BeOne Medicines Gross Profit Historical Data

The historical data trend for BeOne Medicines's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Gross Profit Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 238.22 1,011.38 1,129.45 2,078.86 3,216.15

BeOne Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 528.58 626.72 791.03 831.14 967.26

Competitive Comparison of BeOne Medicines's Gross Profit

For the Biotechnology subindustry, BeOne Medicines's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Gross Profit distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Gross Profit falls into.



BeOne Medicines Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BeOne Medicines's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=3810.241 - 594.089
=3,216

BeOne Medicines's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=1127.824 - 160.56
=967

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,216 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

BeOne Medicines's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=967 / 1127.824
=85.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BeOne Medicines  (NAS:ONC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BeOne Medicines had a gross margin of 85.76% for the quarter that ended in Dec. 2024 => Durable competitive advantage


BeOne Medicines Gross Profit Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Executives
Xiaodong Wang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Hillhouse Capital Advisors, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
John Oyler director, 10 percent owner, officer: Chief Executive Office C/O GENTA INC, 3550 GENERAL ATOMICS CT BLDG 9, SAN DIEGO CA 92121
Chan Henry Lee officer: SVP, General Counsel 55 CAMBRIDGE PARKWAY, SUITE 700W, CAMBRIDGE MA 02142
Lai Wang officer: Global Head of R&D C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Xiaobin Wu officer: President and GM China C/O MOURANT OZANNES CRP SVCS CAYMAN LTD, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Julia Aijun Wang officer: Chief Financial Officer C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Margaret Dugan director C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Jane Huang officer: CMO, Hematology C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Amgen Inc 10 percent owner ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Howard Liang officer: CFO & CSO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Timothy Yung-cheng Chen director LSI LOGIC CORP, 1621 BARBER LANE, MILPITAS CA 95035